

THE OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY

Supplementary Material

- Article Title: Association of Bupropion, Naltrexone, and Opioid Agonist Treatment With Stimulant-Related Admissions Among People With Opioid Use Disorder: A Case-Crossover Analysis
- Authors: Kevin Y. Xu, MD, MPH; Carrie M. Mintz, MD; Ned Presnall, MSW; Laura J. Bierut, MD; and Richard A. Grucza, PhD
- **DOI Number:** 10.4088/JCP.21m14112

List of Supplementary Material for the article

- 1. Methods
- 2. <u>Figure 1</u> Derivation of the Analytic Sample for Sensitivity Analyses
- 3. Figure 2 Derivation of the Final Analytic Sample for Main Outcomes
- 4. <u>Table 1</u> Diagnosis Codes for Stimulant-Related Events and Drug-Related Poisonings
- 5. <u>Table 2</u> Odds of Hospitalization or Emergency Room Admission for any Stimulant-Related Events Associated With Medication Treatment Days, Stratified by Sex, Age, and Year of Insurance Enrollment
- 6. <u>Table 3</u> Odds of Hospitalization or Emergency Room Admission for any Stimulant-Related Events Associated With Medication Treatment Days, Stratified by Stimulant Type and OUD Subpopulation
- 7. <u>Table 4</u> Odds of Hospitalization or Emergency Room Admission for any Stimulant-Related Events Associated With Medication Treatment Days, Stratified by Event Type
- 8. <u>Table 5</u> Odds of Cocaine-Related Hospitalization or Emergency Room Admission Associated With Medication Treatment Days, Stratified by Event Type
- 9. <u>Table 6</u> Odds of Amphetamine-Related Hospitalization or Emergency Room Admission Associated With Medication Treatment Days, Stratified by Event Type

© Copyright 2022 Physicians Postgraduate Press, Inc.



THE JOURNAL OF CLINICAL PSYCHIATRY

THE OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY

- 10. Table 7
 Odds of Hospitalization or Emergency Room Admission for Drug-Related Poisonings (Non-Specific to Stimulant-Related Events)
- 11. <u>Table 8</u> Analysis of Interactions: Odds of Any Cocaine- or Amphetamine-Related Hospitalization or Emergency Room Admission Associated With Medication Treatment Days, Among All Patients With OUD (N=51,084 Individuals)
- 12. <u>Table 9</u> Sensitivity Analyses: Odds of Stimulant-Related Hospitalization or Emergency Room Admission, Controlling for Mirtazapine (Active Comparator) and Proton Pump Inhibitors (Negative Control)

Disclaimer

This Supplementary Material has been provided by the authors as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

Supplementary Methods:

Secondary analyses were conducted stratifying patients by sex, age (under 30, 30+ years), and year of insurance enrollment (2006-2011 vs 2012-2015) (Supplementary Table 2). To evaluate the robustness of our findings, we also conducted analyses stratifying by stimulant subtype (Supplementary Table 3, 5-6) and event (Supplementary Table 4-6). We further conducted subgroup analyses to assess if potential protective effects of bupropion were sustained in patients who were not receiving OUD medications during insurance enrollment (Supplementary Table 3, 4-6). To test the specificity of our findings, we evaluated associations of bupropion, SSRIs, and OUD medications with drug-related poisonings non-specific to stimulants (Supplementary Table 7). In addition, given previous literature showing efficacy of bupropion and naltrexone extended-release in contributing to negative urine drug screens in methamphetamine use disorder,¹² we evaluated potential interactive effects between bupropion and OUD medications (buprenorphine, naltrexone, and methadone) (Supplementary Table 8). Finally, we conducted secondary analyses by evaluating associations of stimulant-related ED and hospital admissions with mirtazapine treatment days, previously found to be associated with decreased methamphetamine use,¹⁶ as well as proton-pump inhibitors treatment days (negative control), which would not be predicted to have large effects on stimulant-related events (Supplementary Table 9).

Secular time trends were controlled using restricted cubic splines (i.e., mathematical transformation that allows for smooth, flexible but non-linear association between time and risk for outcome). Time-invariant variables did not require adjustment, as case-crossover design permits individuals to serve as their own controls

Supplementary Figure 1: Derivation of the analytic sample for sensitivity analyses

304,676 individuals aged 12 and older with a diagnosis of OUD in the MarketScan Databases who had prescription drug coverage and at least one opioid use disorder claim falling during period of enrollment

51,084 individuals who had any stimulant-related events, encompassing 30,584,584 person days in the 1 year before and after index
stimulant-related event (<u>Model 1,Figure 1</u>).

- 17,010 individuals with any stimulant-related fall, injury, or poisoning, spanning 10,519,771 person-days in the 1 year before and after index fall, injury, or poisoning (Model 1, Supplementary Table 4)
 - 12,077 individuals spanning 7,428,702 person-days in the 1 year before and after index cocaine-related fall, injury, or poisoning (Model 1, Supplementary Table 5)
 - 6,148 individuals spanning 3,850,004 person-days in the 1 year before and after index amphetamine-related fall, injury, or poisoning (Model 1, Supplementary Table 6)
- 14,700 individuals with stimulant-related psychotic events, spanning 9,020,250 person-days in the 1 year before and after index psychotic event (Model 2, Supplementary Table 4)
 - 10,290 individuals spanning 6,301,669 person-day in the 1 year before and after index cocaine-related psychotic event (Model 2, Supplementary Table 5)
 - 5,714 individuals spanning 3,520,487 person-days in the 1 year before and after index amphetamine-related psychotic event (Model 2, Supplementary Table 6)

Excluding 24,936 individuals who received any OUD medication (naltrexone, methadone, buprenorphine). Excluding 26,164 individuals who never received any OUD medication (naltrexone, methadone, buprenorphine).

26,148 individuals who did not receive OUD medication during insurance enrollment encompassing 15,489,199 person- days in the 1 year before and after index stimulant-related event (**Model 1**, **Supplementary Table 3**)

- 9,032 individuals with any stimulant-related fall, injury, or poisoning, spanning 5,560,418 person-days in the 1 year before and after index fall, injury, or poisoning.
 (Model 3, Supplementary Table 4)
 - 6,471 individuals spanning 3,975,866 persondays in the 1 year before and after index cocaine-related fall, injury, or poisoning (Model 3, Supplementary Table 5)
 - 3,051 individuals spanning 1,972,655 persondays in the 1 year before and after index amphetamine-related fall, injury, or poisoning (Model 3, Supplementary Table 6)
- 7,905 individuals with stimulant-related psychotic events, spanning 4,803,990 person-days in the 1 year before and after index psychotic event (<u>Model 4,</u> <u>Supplementary Table 4</u>)
 - 5,630 individuals spanning 3,423,119 personday in the 1 year before and after index cocaine-related psychotic event (<u>Model 4.</u> <u>Supplementary Table 5)</u>
 - 3,182 individuals spanning 1,805,328 persondays in the 1 year before and after index amphetamine-related psychotic event (Model 4, Supplementary Table 6)


24,920 individuals who received OUD medication during insurance enrollment encompassing 15,087,351 person-days in the 1 year before and after index amphetamine related event (Model 4, Supplementary Table 3

 8,199 individuals with any stimulant-related fall, injury, or poisoning, spanning 4,956,552 person-days in the 1 year before and after index fall, injury, or poisoning.


- (Model 5, Supplementary Table 4)
 - 5,603 individuals spanning 3,450,712 persondays in the 1 year before and after index cocaine-related fall, injury, or poisoning (Model 5, Supplementary Table 5)
 - 2,965 individuals spanning 1,876,510 persondays in the 1 year before and after index amphetamine-related fall, injury, or poisoning (Model 5, Supplementary Table 6)
- 6,793 individuals with stimulant-related psychotic events, spanning 4,214,038 person-days in the 1 year before and after index psychotic event (Model 6, Supplementary Table 4)
 - 4,658 individuals spanning 2,876,899 personday in the 1 year before and after index cocaine-related psychotic event (Model 6, Supplementary Table 5)
 - 2,743 individuals spanning 1,714,446 persondays in the 1 year before and after index amphetamine-related psychotic event (Model 6, Supplementary Table 6)

Supplementary Figure 2: Derivation of the final analytic sample for main outcomes (Figure 1, Supplementary Tables 2-4) as well as secondary analysis (Supplementary Table 7)

304,676 individuals aged 12 and older with a diagnosis of OUD in the MarketScan Databases who had prescription drug coverage and at least one opioid use disorder claim falling during period of enrollment



- 20,933 (22.7%) with both stimulant-related events and other drug-related poisonings
- 41,135 (44.6%) with stimulant-related events, but not other drug-related poisonings
- 30,151 (32.7%) with other drug-related poisonings, but not stimulant-related events



Supplementary Table 1: Diagnosis Codes for Stimulant-Related Events and Drug-Related Poisonings

Diagnosis	ICD-9/-10-CM diagnosis codes
Any Stimulant Related Admission	'F14' 'F15' 'T40.5' 'T43.6' '305.6' '304.2' '304.4' '305.7' '969.7' '970.0' '970.1' '970.9' '970.81' '970.89'
Any Cocaine Related Admission	'F14' 'T40.5' '305.6' '304.2' '970.81'
Any Amphetamine Related Admission	'F15' '305.7' '304.4' '969.7' '970.0' '970.1' '970.9' 'T43.6' '970.89'
	Any of the following: ('F14' 'F15' 'T40.5' 'T43.6' '305.6' '304.2''304.4' '305.7' '969.7' '970.0' '970.1' '970.9' '970.81' '970.89')
Any Admission for Stimulant-Related Psychotic Event	AND
	Any of the following: ('F20' 'F22' 'F23' 'F24' 'F25' 'F28' 'F29' '292' '293' '295' '297' '298' 'F302' 'F312' 'F315' 'F323' 'F333' '296.04' '296.14' '296.24' '296.34' '296.44' '296.54' '296.64')
	Any of the following: ('F14' 'F15' 'T40.5' 'T43.6' '305.6' '304.2''304.4' '305.7' '969.7' '970.0' '970.1' '970.9' '970.81' '970.89')
	AND
Any Admission for Stimulant-Related Fall, Injury, or Poisoning	Any of the following: ('V01' 'V02' 'V03' 'V04' 'V05' 'V06' 'V10' 'V11' 'V12' 'V13' 'V14' 'V15' 'V16' 'V17' 'V18' 'V20' 'V21' 'V22' 'V23' 'V24' 'V25' 'V26' 'V27' 'V28' 'V29' 'V30' 'V31' 'V32' 'V33' 'V34' 'V35' 'V36' 'V37' 'V38' 'V39' 'V40' 'V41' 'V42' 'V43' 'V44' 'V45' 'V46' 'V47' 'V48' 'V49' 'V50' 'V51' 'V52' 'V53' 'V54' 'V55' 'V56' 'V57' 'V58' 'V59' 'V60' 'V61' 'V62' 'V63' 'V64' 'V65' 'V66' 'V67' 'V68' 'V69' 'V70' 'V71' 'V72' 'V73' 'V74' 'V75' 'V76' 'V77' 'V78' 'V79' 'V80' 'V81' 'V82' 'V83' 'V84' 'V85' 'V86' 'V87' 'V88' 'V99' 'V91' 'V92' 'V93' 'V94' 'V95' 'V96' 'V97' 'W00' 'W01' 'W02' 'W03' 'W04' 'W05' 'W06' 'W07' 'W08' 'W09' 'W10' 'W11' 'W12' 'W13' 'W14' 'W15' 'W16' 'W17' 'W18' 'W19' 'W24' 'W25' 'W26' 'W27' 'W28' 'W29' 'W30' 'W31' 'W32' 'W33' 'W34' 'W45' 'W65' 'W66' 'W67' 'W68' 'W69' 'W70' 'W73' 'W74' 'W78' 'W79' 'X00' 'X01' 'X02' 'X03' 'X04' 'X05' 'X06' 'X08' 'X09' 'X31' 'X40' 'X41' 'X42' 'X43' 'X44' 'X46' 'X47' 'X48' 'X49' 'X60' 'X61' 'X62' 'X63' 'X64' 'X66' 'X67' 'X68' 'X69' 'X70' 'X71' 'X72' 'X73' 'X74' 'X75' 'X76' 'X77' 'X78' 'X79' 'X80' 'X81' 'X82' 'X83' 'X84' 'X85' 'X86' 'X87' 'X88' 'X89' 'X90' 'X91' 'Y09' 'Y09' 'Y01' Y01' Y02' 'Y03' 'Y04' 'Y05' 'Y06' 'Y07' 'Y08' 'Y09' 'Y09' 'Y09.0' 'Y01' 'Y02! 'Y03' 'Y04' 'Y05' 'Y06' 'Y07' 'Y08' 'Y09' 'Y09.0' 'Y09.0' 'Y01' 'Y02! 'Y03' 'Y04' 'Y05' 'Y06' 'Y07' 'Y08' 'Y09' 'Y09.0' 'Y09.1' 'Y09.2' 'Y09.3' 'Y09.9' 'Y00.0' 'Y01' 'Y02' 'Y03' 'Y04' 'Y05' 'Y06' 'Y07' 'Y08' 'Y09' 'Y09.0' 'Y09.1' 'Y09.2' 'Y09.3' 'Y09.9' 'Y00.9' 'Y01' 'Y02' 'Y03' 'Y04' 'Y05' 'Y06' 'Y07' 'Y08' 'Y09' 'Y09.0' 'Y09.0' 'Y09.1' 'Y09.2' 'Y09.3' 'Y09.9' 'Y09.9' 'Y00.9' 'Y01' 'Y02' 'Y03' 'Y04' 'Y05' 'Y06' 'Y07' 'Y08' 'Y09' 'Y09.0' 'Y09.0' 'Y09.1' 'Y09.2' 'Y09.3' 'Y04' 'Y05' 'Y06' 'Y07' 'Y08' 'Y09' 'Y09.0' 'Y09.0' 'Y01' 'Y09.3' 'Y04' 'Y05' 'Y06' 'Y07' 'Y08' 'Y09' 'Y09.0' 'Y01' 'Y09.2' 'Y09.3' 'Y04' 'Y05' 'Y06' 'Y07' 'Y08' 'Y09' 'Y09.0' 'Y01' 'Y09.3' 'Y04' 'Y09.3' 'Y09.0' 'Y01' 'Y09.3' 'Y04' 'Y09.3' 'Y04' 'Y09.3' 'Y09.0' 'Y01' 'Y09.3' 'Y04' 'Y05' 'Y06' 'Y07' 'Y08' 'Y09.3' 'Y09.0' 'Y01' 'Y09.3' 'Y09.3' 'Y00'
	Any of the following: ('F14' 'T40.5' '305.6' '304.2' '970.81')
Any Admission for Cocaine-Related Psychotic Event	AND
	Any of the following: ('F20' 'F22' 'F23' 'F24' 'F25' 'F28' 'F29' '292' '293' '295' '297' '298' 'F302' 'F312' 'F315' 'F323' 'F333' '296.04' '296.14' '296.24' '296.34' '296.44' '296.54' '296.64')
	Any of the following: ('F14' 'T40.5' '305.6' '304.2' '970.81')
	AND
Any Admission for Cocaine-Related Fall, Injury, or Poisoning	Any of the following: ('V01' 'V02' 'V03' 'V04' 'V05' 'V06' 'V10' 'V11' 'V12' 'V13' 'V14' 'V15' 'V16' 'V17' 'V18' 'V20' 'V21' 'V22' 'V23' 'V24' 'V25' 'V26' 'V27' 'V28' 'V29' 'V30' 'V31' 'V32' 'V33' 'V34' 'V35' 'V36' 'V37' 'V38' 'V39' 'V40' 'V41' 'V42' 'V43' 'V44' 'V45' 'V46' 'V47' 'V48' 'V49' 'V50' 'V51' 'V52' 'V53' 'V54' 'V55' 'V56' 'V57' 'V58' 'V59' 'V60' 'V61' 'V62' 'V63' 'V64' 'V65' 'V66' 'V67' 'V68' 'V69' 'V70' 'V71' 'V72' 'V73' 'V76' 'V77' 'V78' 'V79' 'V80' 'V81' 'V82' 'V83' 'V84' 'V85' 'V86' 'V87' 'V88' 'V90' 'V91' 'V92' 'V93' 'V94' 'V95' 'V96' 'V97' 'W00' 'W01' 'W02' 'W03' 'W04' 'W05' 'W06' 'W07' 'W08' 'W09' 'W10' 'W11' 'W12' 'W13' 'W14' 'W15' 'W16' 'W17' 'W18' 'W19' 'W24' 'W25' 'W26' 'W27' 'W28' 'W29' 'W30' 'W31' 'W32' 'W33' 'W34' 'W45' 'W65' 'W66' 'W67' 'W68' 'W69' 'W70' 'W73' 'W74' 'W78' 'W79' 'X00' 'X01' 'X02' 'X03' 'X04' 'X05' 'X06' 'X09' 'X31' 'X44' 'X46' 'X46' 'X47' 'X48' 'X49' 'X60' 'X61' 'X62' 'X64' 'X66' 'X66' 'X65' 'X66' 'X67' 'X68' 'X66' 'X66' 'X67' 'X68' 'X66' 'X66' 'X66' 'X66' 'X66' 'X66' 'X66' 'X66' '

	'X67' X68' X69' X70' X71' X72' X73' X74' X75' X76' X77' X78' X79' X80' X81' X82' X83' X84' X85' X86' X87' X88' 'X89' X90' X91' X92' X93' X94' X95' X96' X97' X98' X99' Y00' Y01' Y02' Y03' Y04' Y05' Y06' Y07' Y08' Y09' 'V09.0' V09.1' V09.2' V09.3' V09.9' V19.0' V19.1' V19.2' V19.3' V19.4' V19.5' V19.6' V19.8' V19.9' V89.0' 'V89.1' V89.2' V89.3' V89.9' Y87.0' Y87.1' 'E800' 'E801' 'E802' 'E803' 'E804' 'E805' 'E806' 'E807' 'E810' 'E811' 'E812' 'E813' 'E814' 'E815' 'E816' 'E817' 'E818' 'E819' 'E820' 'E821' 'E822' 'E823' 'E824' 'E825' 'E826' 'E827' 'E828' 'E829' 'E830' 'E831' 'E832' 'E833' 'E834' 'E835' 'E836' 'E837' 'E838' 'E840' 'E841' 'E842' 'E843' 'E844' 'E845' 'E848' 'E850' 'E851' 'E852' 'E853' 'E854' 'E855' 'E856' 'E857' 'E858' 'E860' 'E861' 'E862' 'E863' 'E864' 'E865' 'E866' 'E867' 'E868' 'E869' 'E881' 'E882' 'E883' 'E884' 'E855' 'E866' 'E867' 'E888' 'E890' 'E891' 'E892' 'E893' 'E894' 'E855' 'E896' 'E897' 'E898' 'E890' 'E901' 'E910' 'E911' 'E918' 'E919' 'E920' 'E922' 'E950' 'E951' 'E952' 'E954' 'E955' 'E956' 'E957' 'E958' 'E959' 'E960' 'E961' 'E962' 'E963' 'E964' 'E965' 'E966' 'E967' 'E968' 'E969' 'E924.1')
Any Admission for Amphetamine- Related Psychotic Event	Any of the following: ('F15' '305.7' '304.4' '969.7' '970.0' '970.1' '970.9' 'T43.6' '970.89') AND Any of the following: ('F20' 'F22' 'F23' 'F24' 'F25' 'F28' 'F29' '292' '293' '295' '297' '298' 'F302' 'F312' 'F315' 'F323' 'F333' '296.04' '296.14' '296.24' '296.34' '296.44' '296.54' '296.64')
Any Admission for Amphetamine- Related Fall, Injury, or Poisoning	Any of the following: ('F15' '305.7' '304.4' '969.7' '970.0' '970.1' '970.9' 'T43.6' '970.89') AND Any of the following: (V01' V02' V03' V04' V05' V06' V10' V11' V12' V13' V14' V15' V16' V17' V18' V20' V21' V22' V23' V24' V25' V26' V27' V28' V29' V30' V31' V32' V33' V34' V35' V36' V37' V38' V39' V40' V41' V42' 'V43' V44' V45' V46' V47' V48' V49' V50' V51' V52' V53' V54' V55' V56' V57' V58' V59' V60' V61' V62' V63' V64' V65' V66' V67' V68' V69' V70' V71' V72' V73' V74' V75' V76' V77' V78' V79' V80' V81' V82' V83' V84' V85' V86' V87' V88' V90' V91' '992' V93' V94' V95' V96' V97' W00' W01' W02' W03' W04' W05' W06' W07' W08' W09' W10' W11' W12' W13' W14' W15' W16' W17' W18' W19' W24' W25' W26' W27' V28' W29' 'W30' W31' W32' W33' W34' W45' W65' W66' W67' W68' W69' W70' W73' W74' W78' W79' X00' X01' X02' 'X03' X04' X05' X06' X08' X09' X31' X40' X41' X42' X43' X44' X46' X47' X48' X49' X60' X61' X62' X63' X64' X66' 'K67' X68' X69' X70' X71' X72' X73' X74' X75' X76' X77' X78' X79' X80' X81' X82' X83' X84' X85' X86' X87' X88' '89' Y90' X91' X92' Y93.3' Y94' Y95' Y96' Y97' Y00' Y01' Y02' Y03' Y04' Y05' Y06' Y07' Y08' Y09' 'V09.0' V09.1' V09.2' V09.3' V09.9' V19.0' V19.1' Y19.2' V19.3' V19.4' V19.5' V19.6' V19.8' V19.9' V89.0' 'V89.1' V89.2' V89.3' Y87.0' Y87.1' 1580' E801' E802' E803' E804' E805' E806' E807' E810' E811' E812' 'E813' E814' E815' E816' E817' E818' E819' E820' E821' E822' E823' E824' E825' E826' E827' E828' E829' E830' 'E831' E832' E833' E834' E855' E856' E857' E858' E880' E861' E863' E864' E865' E866' E867' E868' E869' E851' E852' 'E853' E854' E855' E856' E857' E858' E886' E887' E888' E890' E891' E892' E893' E894' E895' E896' E897' E898' E899' E901' 'E910' E911' E917' E918' E919' E920' E891' E892' E893' E894' E895' E896' E897' E898' E899' E901' 'E910' E911' E917' E918' E919' E920' E922' E953' E954' E955' E956' E957' E958' E959' E950' E957' E958' E959' E950' 'E961' E962' E963' E964' E965' E966' E967' E968' E957' E958' E955' E956' E957' E958' E959' E950' 'E961' E962' E963' E964' E965' E966
Any Admission for Drug-Related Poisonings and Accidents (not specific to stimulant-related events)	'T40' 'T41' 'T42' 'T43' 'T44' 'T45' 'T46' 'T47' 'T48' 'T49' 'T50' 'T51' 'T52' 'T53' 'T54' 'T55' 'T56' 'T57' 'T58' 'T59' 'T60' 'T61' 'T62' 'T63' 'T64' 'T65' '960' '961' '962' '963' '964' '965' '966' '967' '968' '969' '970' '971' '972' '973' '974' '975' '976' '977' '978' '979' '980' '981' '982' '983' '984' '985' '986' '987' '988' '989' 'E850' 'E851' 'E852' 'E853' 'E854' 'E856' 'E856' 'E857' 'E858' 'E860' 'E861' 'E862' 'E863' 'E864' 'E865' 'E866' 'E867' 'E868' 'E869' 'E950' 'E951' 'E952' 'E962' 'E972' 'E975' 'E976' 'E980' 'E981' 'E982'

	Female		Male				
	n=20,440 individuals		n=6,984 individuals				
	OR		I	OR	95% CI		
Bupropion	0.77	0.7	0.85	0.77	0.71	0.84	
SSRIs (active comparator)	0.89	0.85	0.94	0.9	0.85	0.95	
Buprenorphine	0.66	0.61	0.71	0.69	0.65	0.74	
Methadone	0.55	0.47	0.65	0.67	0.52	0.86	
Naltrexone	0.65	0.58	0.72	0.65	0.59	0.72	
P<.0001 for all							
	Age under 30			Age 30+			
	n=27,669 individuals			n=23,415 individuals			
	OR	95% C	I	OR	95% CI		
Bupropion	0.75	0.68	0.82	0.8	0.73	0.88	
SSRIs (active comparator)	0.88	0.84	0.93	0.91	0.86	0.96	
Buprenorphine	0.73	0.69	0.77	0.59	0.55	0.64	
Methadone	0.63	0.5	0.79	0.56	0.47	0.67	
Naltrexone	0.66	0.61	0.72	0.61	0.53	0.7	
P<.0001 for all							
	Years 2012-2015			Years 2006-2011			
	n=23,337 individuals			n= 27,747 individuals			
	OR	95% C	I	OR	95% C	I	
Bupropion	0.84	0.75	0.93	0.74	0.68	0.8	
SSRIs(active comparator)	0.88	0.83	0.94	0.9	0.86	0.94	
Buprenorphine	0.65	0.6	0.7	0.69	0.65	0.73	
Methadone	0.6	0.51	0.7	0.54	0.4	0.72	
Naltrexone	0.64	0.57	0.71	0.65	0.59	0.72	
P<.0001 for all							

Supplementary Table 2: Odds of hospitalization or emergency room admission for any stimulant-related events associated with medication treatment days, stratified by sex, age, and year of insurance enrollment

Supplementary Table 3: Odds of hospitalization or emergency room admission for any stimulant-related events associated with medication treatment days, stratified by stimulant type and OUD subpopulation

			lant-Related	•	Subtypes of Stimulant-Related Events						
		or Amphetamines) Admissions N=51,084			Any Cocaine-Related Admissions n= 35,912 individuals			Any Amphetamine-Related Admissions n= 21,674 individuals			
	Effect	Odds 95% CI Ratio		Odds Ratio	95% CI		Odds Ratio	95% CI			
Patients with			Model 1			Model 2			Model 3		
OUD Not		15,48	9,199 persor	n days	10,87	78,229 perso	n-days	6,48	3,459 persor	1-days	
Receiving OUD	Bupropion Days	0.75	0.67	0.84	0.74	0.64	0.85	0.73	0.62	0.85	
Medication During Insurance Enrollment n= 26,148 individuals	SSRI Days (active comparator)	0.91	0.91 0.86 0.96		0.91	0.84	0.98	0.88	0.81	0.95	
			Model 4		Model 5			Model 6			
		15,08	7,351 persor	n days	10,576,480 person-days			6,521,236 person-days			
Patients with	Bupropion Days	0.78	0.72	0.85	0.78	0.71	0.87	0.79	0.70	0.88	
OUD Receiving OUD	SSRI Days (active comparator)	0.89	0.85	0.93	0.89	0.84	0.94	0.89	0.83	0.95	
Medication	Buprenorphine Days	0.68	0.64	0.71	0.64	0.60	0.67	0.76	0.70	0.82	
During Insurance	Methadone Days	0.59	0.51	0.67	0.58	0.50	0.68	0.62	0.47	0.81	
Enrollment, n=24,920 individuals	Naltrexone (PO, ER) Days	0.64	0.60	0.69	0.67	0.61	0.74	0.59	0.53	0.65	

P<.0001 for all

Abbreviations: SSRI (selective serotonin reuptake inhibitors), PO (oral), ER (extended-release)

Supplementary Table 4: Odds of hospitalization or emergency room admission for any stimulant-related events associated with medication treatment days, stratified by event- type

			sions				
		Admission for Any Stimulant-Related (Cocaine + Amphetamines) Falls or Injuries and Poisonings			Admission for (Cocaine + A		
	Effect	Odds Ratio	95'	% CI	Odds Ratio	959	% CI
All Patients with OUD,		10,51	(Model 1) 19,771 person-	-davs	9,020	(Model 2) 0,250 person-0	davs
n= 51,084 individuals	Bupropion Days	0.77	0.68	0.87	0.73	0.64	0.84
	SSRI Days (active comparator)	0.87	0.81	0.93	0.80	0.74	0.86
	Buprenorphine Days	0.72	0.66	0.79	0.48	0.44	0.54
	Methadone Days	0.59	0.46	0.76	0.26	0.18	0.37
	Naltrexone (PO, ER) Days	0.71	0.61	0.83	0.44	0.37	0.53
Patients with OUD Not Receiving OUD Medication During Insurance Enrollment, n= 26,148 individuals	Bupropion Days SSRI Days (active comparator)	5,56 0.75 0.83	(Model 3) 0,418 person 0.62 0.75	days 0.90 0.92	4,803 0.63 0.80	(Model 4) 3,990 person-o 0.51 0.72	days 0.79 0.89
Patients with OUD		4.05	(Model 5)		(Model 6)		
Receiving OUD Medication During	Bupropion Days	4,95 0.78	6,552 person- 0.67	0.92	4,214 0.80	4,038 person-(0.67	0.94
Insurance Enrollment,	SSRI Days (active comparator)	0.89	0.82	0.97	0.79	0.72	0.87
n=24,920 individuals	Buprenorphine Days	0.73	0.66	0.80	0.49	0.44	0.54
	Methadone Days	0.60	0.46	0.77	0.27	0.19	0.38
	Naltrexone (PO, ER) Days	0.70	0.60	0.83	0.44	0.37	0.53
P<.0001 fo	r all						

Abbreviations: SSRI (selective serotonin reuptake inhibitors), Nal PO (naltrexone Oral), Nal ER (naltrexone extended-release)

Supplementary Table 5: Odds of cocaine-related hospitalization or emergency room admission associated with medication treatment days, stratified by event-type

		Any Cocaine-	Related Falls or Poisonings	r Injuries and	Any Cocaine	-Related Psych	otic Events
	Effect	Odds Ratio	959	% CI	Odds Ratio	959	% CI
All Patients with OUD,		7,42	(Model 1) 8,702 person-c	davs	6,30	(Model 2) 1,669 person-6	days
n= 35,912	Bupropion Days	0.77	0.66	0.90	0.72	0.60	0.85
individuals	SSRI Days (active comparator)	0.88	0.81	0.95	0.80	0.73	0.87
	Buprenorphine Days	0.68	0.60	0.76	0.44	0.39	0.50
	Methadone Days	0.56	0.42	0.74	0.19	0.12	0.29
	Naltrexone (PO, ER) Days	0.77	0.63	0.94	0.48	0.38	0.61
Patients with OUD Not Receiving OUD Medication During Insurance Enrollment, N=18,362 individuals	Bupropion Days SSRI Days (active comparator)	3,97 0.67 0.84	(Model 3) 5,866 person-c 0.52 0.74	days 0.87 0.95	3,42 0.60 0.81	(Model 4) 3,119 person-o 0.45 0.70	lays 0.80 0.93
Patients with OUD Receiving		3,45	(Model 5) 0,712 person-o	days	2,87	(Model 6) 6,899 person-o	lays
OUD Medication	Bupropion Days	0.83	0.68	1.01	0.79	0.64	0.98
During	SSRI Days (active comparator)	0.90	0.81	1.00	0.78	0.69	0.88
Enrollment, n=	Buprenorphine Days	0.68	0.61	0.77	0.44	0.39	0.50
17,937 individuals	Methadone Days	0.56	0.43	0.75	0.20	0.13	0.31
marviadas	Naltrexone (PO, ER) Days	0.77	0.63	0.94	0.49	0.39	0.61

Abbreviations: SSRI (selective serotonin reuptake inhibitors), Nal PO (naltrexone Oral), Nal ER (naltrexone extended-release)

Supplementary Table 6: Odds of amphetamine-related hospitalization or emergency room admission associated with medication treatment days, stratified by event-type

		Any Amphetar a	mine-Related F Ind Poisonings		Any Amphetamine-Related Psychoti Events			
	Effect	Odds Ratio	959	% CI	Odds Ratio	959	% CI	
All Patients with		2.95	(Model 1)	la	2.52	(Model 2)		
OUD, n= 21,674	Bupropion Days	3,85 0.78	0,004 person-c 0.65	0.94	3,52 0.71	0,487 person-0 0.58	0.86	
individuals	SSRI Days (active comparator)	0.84	0.76	0.93	0.79	0.71	0.87	
	Buprenorphine Days	0.81	0.69	0.95	0.58	0.50	0.68	
	Methadone Days	0.69	0.41	1.17	0.46	0.25	0.82	
	Naltrexone (PO, ER) Days	0.57	0.45	0.74	0.37	0.28	0.48	
Patients with OUD Not Receiving OUD Medication During Insurance Enrollment, n= 10,950 individuals	Bupropion Days SSRI Days (active comparator)	1,97 0.80 0.78	(Model 3) 2,655 person-c 0.61 0.67	lays 1.05 0.91	1,80 0.68 0.76	(Model 4) 5,328 person-o 0.50 0.65	lays 0.93 0.89	
Patients with OUD Receiving OUD		1,87	(Model 5) 6,510 person-c	lays	1,71	(Model 6) 4,446 person-o	lays	
Medication During Insurance	Bupropion Days	0.76	0.59	0.98	0.73	0.57	0.94	
Enrollment, n=10,959	SSRI Days (active comparator)	0.89	0.77	1.02	0.80	0.70	0.92	
individuals	Buprenorphine Days	0.81	0.69	0.96	0.58	0.50	0.68	
	Methadone Days	0.69	0.41	1.17	0.46	0.25	0.82	
	Naltrexone (PO, ER) Days	0.56	0.44	0.73	0.36	0.28	0.48	
	I							

Abbreviations: SSRI (selective serotonin reuptake inhibitors), Nal PO (naltrexone Oral), Nal ER (naltrexone extended-release)

Supplementary Table 7: Odds of hospitalization or emergency room admission for drug-related poisonings (non-specific to stimulant-related events)

Admission for All Drug-Related Poisonings,

n= 62,068 individuals, 37,744,460 person-days

<u>Effect</u>	<u>Point</u>	<u>Estimate</u>	<u>95% Confidence</u> Intervals	
Bupropion Days	1	.01	0.94	1.07
SSRI Days (active comparator)	0	.99	0.96	1.03
Buprenorphine Days	0	.62	0.59	0.66
Methadone Days	0	.48	0.41	0.55

Abbreviations: SSRI (selective serotonin reuptake inhibitors), Nal PO (naltrexone Oral), Nal ER (naltrexone extended-release)

Supplementary Table 8: Analysis of Interactions - Odds of any cocaine- or amphetamine-related hospitalization or emergency room admission associated with medication treatment days, among all Patients with OUD (n=51,084 individuals)

		Any Stimulant-Related (Cocaine + Amphetamines) Admissions 15,087,351 person days			Any Cocaine-Related Admissions, 10,576,480 person-days			Any Amphetamine-Related Admissions 6,521,236 person-days		
	<u>Effect</u>	<u>Beta</u>	<u>Standard</u> <u>Error</u>	<u>p-value</u>	<u>Beta</u>	<u>Standard</u> <u>Error</u>	<u>p-value</u>	<u>Beta</u>	<u>Standard</u> <u>Error</u>	<u>p-value</u>
	Bupro days	-0.26	0.03	<.0001	-0.26	0.04	<.0001	-0.28	0.05	<.0001
	Nal (PO,ER)*Bupro	0.04	0.12	0.76	0.00	0.15	0.99	0.19	0.16	0.24
Nal (PO or ER) and Bupro	SSRI days (active comparator)	-0.11	0.02	<.0001	-0.11	0.02	<.0001	-0.12	0.03	<.0001
Interaction	Bupren days	-0.39	0.02	<.0001	-0.46	0.03	<.0001	-0.28	0.04	<.0001
	Methadone days	-0.53	0.07	<.0001	-0.55	0.08	<.0001	-0.47	0.14	0.00
	Nal (PO, ER) Days	-0.44	0.04	<.0001	-0.39	0.05	<.0001	-0.55	0.06	<.0001
	Bupro days	-0.26	0.03	<.0001	-0.26	0.04	<.0001	-0.27	0.05	<.0001
	Methadone*Bupro	0.11	0.48	0.81	-0.39	0.58	0.51	0.56	0.81	0.49
Methadone	SSRI days (active comparator)	-0.11	0.02	<.0001	-0.11	0.02	<.0001	-0.12	0.03	<.0001
and Bupro Interaction	Bupren days	-0.39	0.02	<.0001	-0.46	0.03	<.0001	-0.28	0.04	<.0001
	Methadone days	-0.53	0.07	<.0001	-0.55	0.08	<.0001	-0.48	0.14	0.00
	Nal (PO, ER) Days	-0.44	0.04	<.0001	-0.39	0.05	<.0001	-0.52	0.05	<.0001
	Bupro days	-0.27	0.03	<.0001	-0.27	0.04	<.0001	-0.30	0.05	<.0001
	Bupren*Bupro	0.14	0.10	0.18	0.09	0.13	0.50	0.34	0.14	0.01
Bupren and	SSRI days (active comparator)	-0.11	0.02	<.0001	-0.11	0.02	<.0001	-0.12	0.03	<.0001
Bupro Interaction	Bupren days	-0.40	0.03	<.0001	-0.46	0.03	<.0001	-0.29	0.04	<.0001
	Methadone days	-0.53	0.07	<.0001	-0.55	0.08	<.0001	-0.47	0.14	0.00
	Nal (PO, ER) Days	-0.44	0.04	<.0001	-0.39	0.05	<.0001	-0.52	0.05	<.0001

Abbreviations: SSRI (selective serotonin reuptake inhibitors), Bupro (bupropion), Bupren (buprenorphine), Meth (methadone), Nal PO (naltrexone Oral), Nal ER (naltrexone extended-release)

Supplementary Table 9: Sensitivity Analyses-Odds of stimulant-related hospitalization or emergency room admission, controlling for mirtazapine (active comparator) and proton pump inhibitors (negative control)

	Any Stimulant-Related (Cocaine + Amphetamines) Events 30,567,174 person days			,	aine-Related Events, 7,716 person-days	,	Any Amphetamine-Related Events 13,001,584 person-days			
Effect	<u>Point</u> <u>Estimate</u>	<u>95% CI</u>		<u>Point</u> <u>Estimate</u>	<u>95% CI</u>		<u>Point</u> Estimate	<u>95% CI</u>		
Bupro days	0.77	0.72	0.82	0.76	0.70	0.83	0.76	0.70	0.83	
Bupren days	0.67	0.64	0.70	0.75	0.70	0.81	0.64	0.60	0.67	
Methadone days	0.57	0.49	0.65	0.62	0.47	0.81	0.55	0.47	0.64	
Nal (PO,ER) Days	0.65	0.60	0.70	0.59	0.53	0.66	0.68	0.62	0.74	
Mirtazapine days (active comparator)	0.90	0.84	0.98	0.84	0.75	0.93	0.88	0.80	0.97	
PPI days (negative control)	0.88	0.82	0.94	0.87	0.78	0.97	0.89	0.82	0.96	

Abbreviations: Bupro (bupropion), Bupren (buprenorphine), Nal PO (naltrexone Oral), Nal ER (naltrexone extended-release), PPI (proton pump inhibitor)